Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKL35501 and SKL35502 in Advanced Solid Tumors
NCT07812805Phase 1Recruiting
- Sponsor
- SK Life Science, Inc.
- Start
- Aug 2026
- Primary completion
- Jul 2030
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of FL-091 in solid tumor, colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and 4 more (2 arms), sponsored by SK Life Science, Inc. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events Following SKL35502 Administration at 15 days, Absorbed Radiation Dose to Prespecified Normal Organs Following SKL35502 Administration at 7 days and 14 more. Started Aug 2026; status: recruiting.
02
Drugs
FL-091
03
Conditions
solid tumorcolorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)biliary tract cancer (BTC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT07812805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07812805.